Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | General Counsel | September 11, 2026 | September 16, 2026 |
| Teligent, Inc.TLGT · Entity 134764 | General Counsel | February 19, 2019 | February 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date September 11, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 598,489 |
Reported balance
After 2026-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-11 · Sale · Disposed 75,364 · Balance 598,489 F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
Teligent, Inc.
Report date February 19, 2019 · Filed February 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2029-02-19 | Direct | 193,712 |
Reported balance
After 2019-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-19 · Grant · Acquired 193,712 · Balance 193,712 F1: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on February 19, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on February 19, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 16, 2026 00:27 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 75,364 | $3.40 | $256,463.69 |
DisclosureSEC source: 0001140361-26-036688 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 598,489 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 21:30 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 631 | $3.38 | $2,133.41 |
DisclosureSEC source: 0001140361-26-033915 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,853 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 21:50 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,493 | $3.38 | $11,809.83 |
DisclosureSEC source: 0001140361-26-033413 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 674,484 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 662 | $3.01 | $1,995.27 |
DisclosureSEC source: 0001140361-26-022446 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 677,977 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| May 13, 2026 Filed May 14, 2026 20:22 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,361 | $3.61 | $12,119.77 |
DisclosureSEC source: 0001140361-26-021321 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 678,639 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:09 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,376 | $3.34 | $4,593.09 |
DisclosureSEC source: 0001140361-26-006317 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 682,000 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:42 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 12,253 | $3.31 | $40,581.94 |
DisclosureSEC source: 0001140361-26-006047 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 683,376 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 468,187 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001140361-26-005410 · form4.xml · derivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,187 Underlying: Common Stock · 468,187 shares Expires 2036-02-11 F3 · derivative.exercise_date: This option represents a right to purchase a total of 468,187 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 311,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-005410 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,629 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · shares: Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,646 | $2.98 | $4,910.02 |
DisclosureSEC source: 0001140361-25-042854 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,816 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| November 03, 2025 Filed Nov 10, 2025 21:25 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-041393 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,462 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: Represent RSUs that convert to common stock on a one-for-one basis. The RSUs will become fully vested on November 3, 2026. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:18 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-034422 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,462 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on September 8, 2026, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 21:00 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 588 | $3.00 | $1,761.65 |
DisclosureSEC source: 0001140361-25-032090 · form4.xml · nonDerivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,462 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:00 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,004 | $3.07 | $3,077.26 |
DisclosureSEC source: 0001140361-25-032090 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,050 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:35 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 12,109 | $3.02 | $36,557.07 |
DisclosureSEC source: 0001140361-25-031760 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,054 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 587 | $6.45 | $3,783.80 |
DisclosureSEC source: 0001140361-25-020159 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,163 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 946 | $6.53 | $6,175.49 |
DisclosureSEC source: 0001140361-25-019898 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,750 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,222 | $10.58 | $34,088.76 |
DisclosureSEC source: 0001140361-25-005846 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,696 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 134,642 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001140361-25-004297 · form4.xml · derivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,642 Underlying: Common Stock · 134,642 shares Expires 2035-02-11 F2 · derivative.exercise_date: This option represents a right to purchase a total of 134,642 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 90,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-004297 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,918 F1 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,175 | $13.05 | $15,338.45 |
DisclosureSEC source: 0001140361-24-047754 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,560 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,027 | $18.50 | $19,003.61 |
DisclosureSEC source: 0001140361-24-037931 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,735 F1 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:29 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,048 | $23.35 | $24,470.80 |
DisclosureSEC source: 0001140361-24-026873 · form4.xml · nonDerivative · entry 4 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,762 F4 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:29 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 2,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026873 · form4.xml · derivative · entry 5 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,947 Underlying: Common Stock · 2,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:29 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 2,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026873 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:48 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 4,100 | $29.33 | $120,257.10 |
DisclosureSEC source: 0001140361-24-011168 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,680 F1 · price: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.37. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 49,091 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001140361-24-008890 · form4.xml · derivative · entry 3 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,091 Underlying: Common Stock · 49,091 shares Expires 2034-02-16 F5 · derivative.exercise_date: This option represents a right to purchase a total of 49,091 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 16,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008890 · form4.xml · nonDerivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,780 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F4 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,576 | $29.84 | $106,700.69 |
DisclosureSEC source: 0001140361-24-008890 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,136 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F2 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F3 · shares: The shares of common stock were sold by the Reporting Person pursuant to an exemption to the Lock-Up Agreement in order to pay tax withholding obligations in connection with the vesting of RSUs. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 9,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008360 · form4.xml · derivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,367 Underlying: Common Stock · 9,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 9,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008360 · form4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 29,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-007486 · form4.xml · derivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,079 Underlying: Common Stock · 29,079 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 87,147 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0001140361-23-007486 · form4.xml · derivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,147 Underlying: Common Stock · 87,147 shares Expires 2033-02-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 87,147 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed May 20, 2024 20:29 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 16,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026873 · form4.xml · derivative · entry 7 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,947 shares Expires not disclosed F1 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F2 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed May 20, 2024 20:29 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 16,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026873 · form4.xml · nonDerivative · entry 3 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,810 F1 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F2 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F2 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:24 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 28,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-029888 · form4.xml · derivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,763 Underlying: Common Stock · 28,763 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units will become fully vested on August 12, 2025. F3 · derivative.expiration_date: The restricted stock units will become fully vested on August 12, 2025. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:24 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 20,318 | $0.00 Strike: $17.47 | $0.00 |
DisclosureSEC source: 0001140361-22-029888 · form4.xml · derivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,318 Underlying: Common Stock · 20,318 shares Expires 2032-08-11 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,318 shares of the Issuer's common stock, which will become fully vested and exercisable on August 12, 2025. Read SEC document |
| August 12, 2022 Filed May 20, 2024 20:29 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 28,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026873 · form4.xml · derivative · entry 6 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,763 shares Expires not disclosed F2 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F3 · security: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F3 · derivative.exercise_date: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025. F3 · derivative.expiration_date: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025. Read SEC document |
| August 12, 2022 Filed May 20, 2024 20:29 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 28,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026873 · form4.xml · nonDerivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,863 F2 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F3 · security: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025. F2 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 23:55 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $23.04 | $0.00 |
DisclosureSEC source: 0001140361-21-040891 · form4.xml · derivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-06 F1 · derivative.exercise_date: This option represents a right to purchase a total of 100,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on December 6, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:00 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 193,712 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001144204-19-009335 · tv514231_4.xml · derivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,712 Underlying: Common Stock · 193,712 shares Expires 2029-02-19 F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on February 19, 2020. Read SEC document |
| April 25, 2018 Filed Oct 22, 2018 21:45 UTC | Teligent, Inc. TLGT · Entity 134764 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-054834 · tv505291_4.xml · derivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the right to receive one share of the Issuer's common stock. F1 · kind: Vesting of restricted stock units ("RSUs") granted to the Reporting Person on April 25, 2017. F3 · derivative.exercise_date: The RSUs vest ratably on an annual basis for three years beginning on April 25, 2018. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. F3 · derivative.expiration_date: The RSUs vest ratably on an annual basis for three years beginning on April 25, 2018. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| April 25, 2018 Filed Oct 22, 2018 21:45 UTC | Teligent, Inc. TLGT · Entity 134764 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-054834 · tv505291_4.xml · nonDerivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of restricted stock units ("RSUs") granted to the Reporting Person on April 25, 2017. Read SEC document |
| March 22, 2018 Filed Apr 2, 2018 16:06 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantRestricted Stock Unit · Derivative | 11,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-018612 · tv490094_form4.xml · derivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,052 Underlying: Common Stock · 11,052 shares Expires 2028-03-22 F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on March 22, 2019. Read SEC document |
| March 22, 2018 Filed Apr 2, 2018 16:06 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 22,105 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001144204-18-018612 · tv490094_form4.xml · derivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,105 Underlying: Common Stock · 22,105 shares Expires 2028-03-22 F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on March 22, 2019. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 16:45 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-17-004327 · wf-form4_149323953987247.xml · derivative · entry 2 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-04-25 F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on April 25, 2018. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 16:45 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001628280-17-004327 · wf-form4_149323953987247.xml · derivative · entry 1 Wilson Martin · CIK 0001704342 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-04-25 F1 · derivative.exercise_date: These securities were issued pursuant to the terms of the Issuer's 2016 Equity Incentive Plan as part of the Reporting Person's annual compensation. One-third of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on April 25, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.